Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Maintenance Notification: On Saturday January 19th 2019 you will not be able to log into this website due to planned maintenance work.

If you have any questions or concerns, please feel free to reach out to your support team at clientservices@pharma.informa.com

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Congestion Continues In Private Label Mucinex Pipeline; Court Rules Against Mutual

This article was originally published in The Tan Sheet

22 Apr 2016
News

Malcolm Spicer @TheTanSheet malcolm.spicer@informa.com

Executive Summary

A ruling for RB n Pennsylvania federal court comes as it girds for increased competition from additional guaifenesin expectorant formulations that are the equivalents of Mucinex brand products and that Perrigo is marketing under license from manufacturer Allergan.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United States

Europe

Ireland

United Kingdom

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Consumer BioPharmaceutical United States

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS108297

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS108297

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Congestion Continues In Private Label Mucinex Pipeline; Court Rules Against Mutual

News

Executive Summary

Related Content

Mutual Alleges Mucinex Monopoly In Extended-Release Guaifenesin

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert